Wall Street brokerages predict that Guardant Health Inc (NASDAQ:GH) will report earnings of ($0.39) per share for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for Guardant Health’s earnings. The highest EPS estimate is ($0.34) and the lowest is ($0.45). Guardant Health reported earnings of ($1.94) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 79.9%. The business is scheduled to report its next quarterly earnings report on Monday, November 18th.

According to Zacks, analysts expect that Guardant Health will report full year earnings of ($1.27) per share for the current financial year, with EPS estimates ranging from ($1.33) to ($1.23). For the next financial year, analysts expect that the firm will post earnings of ($1.29) per share, with EPS estimates ranging from ($1.59) to ($0.90). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research firms that follow Guardant Health.

Guardant Health (NASDAQ:GH) last posted its quarterly earnings results on Tuesday, August 6th. The company reported ($0.13) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.34) by $0.21. The business had revenue of $53.98 million during the quarter, compared to the consensus estimate of $35.97 million. Guardant Health had a negative return on equity of 22.93% and a negative net margin of 60.08%. The firm’s revenue for the quarter was up 178.5% compared to the same quarter last year. During the same period in the prior year, the company posted ($1.75) EPS.

GH has been the subject of several analyst reports. Cowen set a $110.00 price objective on Guardant Health and gave the company a “buy” rating in a report on Wednesday, August 7th. Zacks Investment Research downgraded Guardant Health from a “strong-buy” rating to a “hold” rating in a research note on Saturday, August 10th. JPMorgan Chase & Co. upped their target price on shares of Guardant Health from $90.00 to $135.00 and gave the company an “overweight” rating in a research report on Wednesday, August 7th. Finally, Canaccord Genuity reiterated a “buy” rating and set a $125.00 price target (up from $96.00) on shares of Guardant Health in a research note on Wednesday, August 7th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $111.80.

NASDAQ GH traded down $5.49 on Wednesday, hitting $75.22. The stock had a trading volume of 64,743 shares, compared to its average volume of 975,433. Guardant Health has a 52-week low of $27.04 and a 52-week high of $112.21. The stock has a market cap of $7.43 billion and a price-to-earnings ratio of -26.83. The business’s fifty day moving average price is $93.88 and its 200 day moving average price is $81.86.

In other news, insider Richard B. Lanman sold 63,075 shares of the firm’s stock in a transaction on Friday, August 9th. The stock was sold at an average price of $105.25, for a total value of $6,638,643.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Ian T. Clark sold 9,683 shares of the business’s stock in a transaction that occurred on Tuesday, August 6th. The shares were sold at an average price of $89.75, for a total transaction of $869,049.25. The disclosure for this sale can be found here. In the last 90 days, insiders sold 1,004,867 shares of company stock worth $100,483,206. Company insiders own 13.00% of the company’s stock.

A number of institutional investors and hedge funds have recently made changes to their positions in GH. River & Mercantile Asset Management LLP acquired a new stake in shares of Guardant Health in the 2nd quarter valued at $339,000. Treasurer of the State of North Carolina bought a new position in Guardant Health in the 2nd quarter valued at $1,188,000. WealthPLAN Partners LLC acquired a new position in Guardant Health in the second quarter worth $210,000. Griffin Asset Management Inc. boosted its stake in Guardant Health by 1.4% in the second quarter. Griffin Asset Management Inc. now owns 11,336 shares of the company’s stock worth $979,000 after purchasing an additional 154 shares in the last quarter. Finally, Magnetar Financial LLC bought a new stake in shares of Guardant Health during the second quarter worth $432,000. Hedge funds and other institutional investors own 81.40% of the company’s stock.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes; and GuardantOMNI, a broader gene panel, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications.

Featured Story: What is a management fee?

Get a free copy of the Zacks research report on Guardant Health (GH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Guardant Health (NASDAQ:GH)

Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.